In brief
- OpenAI built GPT-4b micro, a downsized model specialized for protein engineering, in collaboration with longevity startup Retro Biosciences.
- The model designed new variants of the Yamanaka factors, proteins used to reprogram adult cells into stem cells, achieving 50-fold higher efficiency in lab tests.
- Researchers say the results show how AI could accelerate life sciences and longevity research, though the work remains early and lab-based.
AI isn’t just cranking out code, images, and songs anymore. Now it can redesign the proteins inside your cells.
On a company blog post, OpenAI just announced that it collaborated with Retro Biosciences, a Silicon Valley longevity startup, to train a specialized model called GPT-4b micro. Unlike the chatbots you know, this model wasn’t fine-tuned for banter or brainstorming. Instead, it was trained on protein sequences, biological text, and 3D structure data so it could propose entirely new variants of proteins used in regenerative medicine.
The results were surprising: GPT-4b micro successfully re-engineered two of the famous Yamanaka factors—proteins that won a Nobel Prize for their a
Go to Source to See Full Article
Author: Josh Quittner
